Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
EARLY_PHASE1
INTERVENTIONAL
2017-11-01
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intratracheal Umbilical Cord-derived Mesenchymal Stem Cell for the Treatment of Bronchopulmonary Dysplasia (BPD)
NCT03645525
Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulmonary Dysplasia(BPD) in Premature Infants
NCT06788470
Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies
NCT02443961
Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.
NCT06270199
Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia
NCT01207869
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
transplantation of hUCB-derived MSCs should be effective in treating BPD. The safety and efficacy of MSC transplantation for prevention of BPD has not been tested previously, however.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
transplantation of mesenchymal stem cell
transplantation of mesenchymal stem cell will be given to the infants with BPD.
transplantation of mesenchymal stem cell
allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
no transplantation of mesenchymal stem cell
transplantation of mesenchymal stem cell will be not given to the infants with BPD.
no transplantation of mesenchymal stem cell
MSC transplantation will be not given to preterm infants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transplantation of mesenchymal stem cell
allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
no transplantation of mesenchymal stem cell
MSC transplantation will be not given to preterm infants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Month
3 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospital of Chongqing Medical University
OTHER
Chongqing Maternal and Child Health Hospital
OTHER
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Long,MD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
stem cell for BPD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.